GREY:ATBPF - Post by User
Comment by
WalkOverTheStrton May 12, 2021 2:52pm
138 Views
Post# 33184296
RE:RE:Catalyst
RE:RE:CatalystAgree with majority esp if Dan and team GIA but not:
"I don't think that new pipeline success would be much of a catalyst for institutions to risk capital either because the market/institutions have heard the H2S story for many, many years.".
I've followed RNAI for years which has been in the works since the early 2000's and just like HS2 was on the back burner until recently (last 2-3 years see ALNY, ARWR, Dicerna, etc.). It wasn't until mutliple drugs in human trials proceeded successfully esp with the trail blazer ALNY that the value of those companies increased dramatically.
I'll state this until my fingers fall off - there is no platform without multiple successful human trials. We can debate why Dan and team decided to not run multiple human drugs (capital, focus, delays, etc.) but BP as you pointed out is cautious and prudent. One drug is PH3 with no other human trials to point to is a weakness if mgmt is trying to sell the entire company (which I believe is the final outcome). i'd also counter that Otel probability of success is higher than 60% based on the entensive studies performed on NSAIDS as well as the PH2 A and B studies...